The role of imaging in the diagnosis, staging, and management of testicular cancer

American Journal of Roentgenology

Volumn 191, Issue 2, 2008, Pages 387-395

  Sohaib, S Aslam ^a   Koh, Dow Mu ^a   Husband, Janet E ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

CT; Genitourinary imaging; Germ cell tumor; Oncologic imaging; Testicular cancer

Indexed keywords

FLUORODEOXYGLUCOSE;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; GERM CELL TUMOR; HUMAN; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATIENT CARE; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; SEMINOMA; TESTIS CANCER;

DIAGNOSTIC IMAGING; HUMANS; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; POPULATION SURVEILLANCE; TESTICULAR NEOPLASMS;

EID: 49249113728     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.2758     Document Type: Review

References (45)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43-66
2. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 2006; 367:754-765
3. Sobin LH, Wittekind CH, eds. TNM: classification of malignant tumours, 6th ed. New York, NY: Wiley-Liss, 2002
4. Krege S, Beyer J, Souchon R, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG) - part I. Eur Urol 2008; 53:473-496
5. [No authors listed]. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997; 15:594-603
6. Kondagunta GV, Sheinfeld J, Motzer RJ. Recommendations of follow-up after treatment of germ cell tumors. Semin Oncol 2003; 30:382-389
7. Tsili AC, Tsampoulas C, Giannakopoulos X, et al. MRI in the histologic characterization of testicular neoplasms. AJR 2007; 189:1473; [Web] W331-W337
8. Kim W, Rosen MA, Langer JE, Banner MP, Siegelman ES, Ramchandani P. US MR imaging correlation in pathologic conditions of the scrotum. RadioGraphics 2007; 27:1239-1253
9. Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR 1997; 169:521-525
10. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987; 2:294-298
11. Thompson PI, Nixon J, Harvey VJ. Disease relapse in patients with stage I nonseminomatous germ cell tumor of the testis on active surveillance. J Clin Oncol 1988; 6:1597-1603
12. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995; 154:1045-1049
13. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992; 10:1762-1768
14. Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchidectomy alone in testicular stage I nonseminomatous germ-cell tumours. Lancet 1982; 2:678-680
15. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999; 53:808-811
16. Spermon JR, Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int 2002; 89: 549-556
17. Rockall AG, Sohaib SA, Harisinghani MG, et al. Diagnostic performance of nanoparticle-enhanced magnetic resonance imaging in the diagnosis of lymph node metastases in patients with endometrial and cervical cancer. J Clin Oncol 2005; 23:2813-2821
18. Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology 2005; 66:1066-1071
19. Bellin MF, Lebleu L, Meric JB. Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography. Abdom Imaging 2003; 28:155-163
20. Koh DM, Brown G, Temple L, et al. Rectal cancer: mesorectal lymph nodes at MR imaging with USPIO versus histopathologic findings - initial observations. Radiology 2004; 231:91-99
21. Huddart RA, Joffe JK. Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin Oncol 2006; 18:693-695
22. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2006; 24:467-475
23. Travis LB, Fossa SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005; 97:1354-1365
24. Sohaib SA, Huddart R, Dearnaley DP, Horwich A, Husband J. Sensitivity of MRI scanning in the diagnosis of retroperitoneal disease in testicular germ cell tumours. (abstr) AJR 2005; 184[American Roentgen Ray Society 105th Annual Meeting Abstract Book suppl]:63
25. O'Malley M, Chung P, Warde P, Jang H, Jhaveri K, Khalili K. Testicular cancer surveillance: comparison of low dose and standard dose abdominal/ pelvic CT using a 64 slice multidetector scanner. In: Radiological Society of North America scientific assembly and annul meeting program. Oak Brook, IL: RSNA, 2006:531
26. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003; 111:76-83; discussion 83-85
27. Harvey ML, Geldart TR, Duell R, Mead GM, Tung K. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer: a necessary risk? Ann Oncol 2002; 13:237-242
28. White PM, Howard GC, Best JJ, Wright AR. The role of computed tomographic examination of the pelvis in the management of testicular germ cell tumours. Clin Radiol 1997; 52:124-129
29. Crawford SM, Rustin GJ, Begent RH, Newlands ES, Bagshawe KD. Safety of surveillance in the management of stage I anaplastic germ cell tumours of the testis. Br J Urol 1988; 61:250-253
30. Rustin GJ, Mead GM, Stenning SP, et al.; National Cancer Research Institute Testis Cancer Clinical Studies Group. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 - the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007; 25:1310-1315
31. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging 2003; 30: 396-402
32. Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999; 54:900-904
33. Huddart R, O'Doherty M, Padhani AR, et al. Prospective study of 18 FDG PET in the prediction of relapse in patients with high risk clinical stage I non-seminomatous germ cell cancer. Eur J Cancer 2005:227
34. Warde P, Specht L, Horwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20:4448-4452
35. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006; 24:5503-5511
36. Dieckmann KP, Albers P, Classen J, et al. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol 2005; 173: 824-829
37. Husband JE, Barrett A, Peckham MJ. The role of computer tomography in the assessment of tumour volume in patients with malignant testicular teratoma. Br J Radiol 1981; 15:50-53
38. Connor S, Guest P. Conversion of multiple solid testicular teratoma metastases to fatty and cystic liver masses following chemotherapy: CT evidence of "maturation." Br J Radiol 1999; 72:1114-1116
39. Shahidi M, Norman AR, Dearnaley DP, Nicholls J, Horwich A, Huddart RA. Late recurrence in 1263 men with testicular germ cell tumors: multivariate analysis of risk factors and implications for management. Cancer 2002; 95:520-530
40. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034-1039
41. Lewis DA, Tann M, Kesler K, McCool A, Foster RS, Einhorn LH. Positron emission tomography scans in postchemotherapy seminoma patients with residual masses: a retrospective review from Indiana University Hospital. J Clin Oncol 2006; 24:e54-e55
42. Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998; 39:815-822
43. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83:863-869
44. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996; 14:1637-1641
45. Flechon A, Culine S, Theodore C, Droz JP. Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol 2005; 48:957-963